This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does AB InBev (BUD) Stock Have Potential to Rebound in 2019?
by Zacks Equity Research
AB InBev (BUD) suffers on account of softness in the beer industry, particularly in the United States, which is hurting its sales. However, its recent venture in cannabis space is encouraging.
5 Best-Performing IPOs of 2018
by Nitish Marwah
Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.
Company News For Dec 21, 2018
by Zacks Equity Research
Companies In The News Are: WBA,BB,CCL,TLRY,BUD
Do Options Traders Know Something About Tilray (TLRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
AB InBev (BUD) Enters Booming Cannabis Realm With Tilray Deal
by Zacks Equity Research
AB InBev (BUD) announces partnership with the leading marijuana producer, Tilray.
Tilray Stock Up on Medical Cannabis Collaboration With Sandoz
by Zacks Equity Research
Tilray (TLRY) expands its previous collaboration deal with Sandoz, a generic arm of Novartis, to supply medical cannabis globally using the latter's supply chain.
Company News For Dec 19, 2018
by Zacks Equity Research
Companies In The News Are: CBS,BA,DRI,TLRY,NVS
What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL
by Ryan McQueeney
Ryan McQueeney recaps news involving the U.S. housing market, Tilray, Johnson & Johnson, and Oracle. Later, the host provides an outlook for General Electric stock in 2019.
Tilray, Inc. (TLRY) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $75.13 in the latest trading session, marking a -0.52% move from the prior day.
4 Reasons Why Pot Stocks & ETF Could Be on a High in 2019
by Sanghamitra Saha
These are the factors that could send marijuana stocks and ETF high in 2019.
Why Tilray (TLRY) Could Be Positioned for a Slump
by Zacks Equity Research
Tilray (TLRY) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Are There Any Dividend-Paying Cannabis Stocks?
by Ryan McQueeney
Cannabis stocks have been one of the investing world's top stories in 2018, but for many, these speculative plays are far too unpredictable. Are there any stable, dividend-paying marijuana stocks to buy right now?
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $102.94, moving +0.48% from the previous trading session.
Options Traders Expect Huge Moves in Tilray (TLRY) Stock
by Zacks Equity Research
Tilray (TLRY) needs investors to pay close attention to the stock based on moves in the options market lately.
Legal Pot Shops & Likely IPOs: Is Hemp the Next Big Thing?
by Nitish Marwah
Increasing tolerance and gradual legalization of marijuana has been an increasing trend across America.
Top and Flop ETFs of Last Week
by Sanghamitra Saha
Inside the winning and losing ETFs of the last week.
What Went Wrong With the Marijuana ETF on Wednesday?
by Sanghamitra Saha
Downbeat earnings have weighed on the marijuana ETF lately. Should you buy the dip or wait on the sidelines?
Cannabis Stocks Reporting Earnings & News from HD, AAPL, TSN
by Ryan McQueeney
Ryan McQueeney discusses the latest trade war developments and recaps earnings results from Home Depot and Tyson Foods. He also touches on Apple's supplier concerns. Later, the host chats with Dave Bartosiak about the marijuana stocks reporting earnings this week.
Cronos (CRON) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.
The Earnings Charts of 3 Top Cannabis Stocks
by Tracey Ryniec
The cannabis stocks are hot but will their earnings reports be too?
The Zacks Analyst Blog Highlights: Tilray, Walmart and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Walmart and NVIDIA
Upcoming Earnings to Watch: TLRY, WMT, NVDA
by Ryan McQueeney
U.S. stocks fell sharply in morning trading, as concerns about slumping oil prices, a hotter-than-expected PPI, and a more hawkish Fed cooled Wall Street's post-election bullishness. Investors will now turn to the last wave of Q3 earnings reports for clues on what is next for this market
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
Why Marijuana Stocks & ETF Soared Today
by Neena Mishra
Pot stocks soared today as Jeff Sessions' exit and midterm elections have created a more favorable political environment for the industry.